Dear Customers, We’re excited to announce that our MYO HOME training device will soon be compatible with InBody scales through a new update. With this update, you’ll be able to receive more accurate body composition analyses. We will announce the specific...
Muscle atrophy solution company M20 is joining forces with InBody (041830), the world’s leading body composition analysis company. Following their partnership with Ceragem’s US subsidiary, this collaboration is expected to accelerate M20’s growth in both domestic and...
M20 is accelerating its entry into the US healthcare market in collaboration with Ceragem. The two companies aim to maximize synergy by leveraging M20’s diverse content and Ceragem’s extensive network. Establishing a Local Subsidiary in LA and Collaborating on MYO...
Professor Seok-Won Jeong of Konkuk University Hospital’s Orthopedic Surgery Department has proven the effectiveness of treating muscle atrophy using medium and low-frequency stimulation. “Resolving muscle atrophy through carrier frequency stimulation without...
M20, an AI platform company specializing in solutions for muscle atrophy, has officially entered the U.S. market. Following their success in Ho Chi Minh City, Vietnam, M20 has opened an Esoco Fit offline store in Washington, D.C., with plans to open another store in...
M20, a health care platform company specializing in muscular atrophy solutions, has announced a collaborative research and development partnership with KSB Twogen, a bio-venture company focused on developing new drugs for muscular diseases. KSB Twogen specializes in...
